The latest price target for PTC Therapeutics (NASDAQ:PTCT) was reported by Citigroup on June 9, 2026. The analyst firm set a price target for $108.00 expecting PTCT to rise to within 12 months (a possible 27.92% upside). 33 analyst firms have reported ratings in the last year.

The latest analyst rating for PTC Therapeutics (NASDAQ:PTCT) was provided by Citigroup, and PTC Therapeutics their buy rating.

The last upgrade for PTC Therapeutics Inc happened on May 27, 2026 when Jefferies raised their price target to $85. Jefferies previously had a hold for PTC Therapeutics Inc.

The last downgrade for PTC Therapeutics Inc happened on March 30, 2026 when Jefferies changed their price target from $91 to $76 for PTC Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PTC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PTC Therapeutics was filed on June 9, 2026 so you should expect the next rating to be made available sometime around June 9, 2027.

While ratings are subjective and will change, the latest PTC Therapeutics (PTCT) rating was a with a price target of $75.00 to $108.00. The current price PTC Therapeutics (PTCT) is trading at is $84.43, which is within the analyst’s predicted range.